Articles tagged with Amyotrophic Lateral Sclerosis
Researchers found that astrocytes become pro-inflammatory and lose protective functions in ALS, leading to toxic build-up of glutamate that damages motor neurons. The study also identified distinct molecular patterns in astrocytes associated with different ALS-causing genetic mutations.
A UMass Chan clinical trial demonstrates the safety and efficacy of an antisense oligonucleotide in suppressing mutant C9ORF72, a common cause of familial ALS. The treatment led to reduced levels of neurotoxins and stable or improved ALS functional scores.
Researchers have identified a new molecular component of Amyotrophic Lateral Sclerosis (ALS) pathological aggregates, a circular RNA called circ-Hdgfrp3. This circular RNA plays a crucial role in the formation and progression of ALS, highlighting its potential as a therapeutic target.
A study of 19,000 NFL players found a significantly higher incidence of ALS diagnosis and death among players compared to the U.S. male population.
Researchers have determined the molecular structure of TDP-43 aggregates extracted from human brains, shedding light on its role in neurodegenerative diseases like ALS. The discovery may lead to the development of targeted therapies and diagnostic tests.
A new Northwestern study reveals that brain motor neurons degenerate early in diseases like ALS, sending warning signals and showing defects. Targeting the brain's motor neurons could lead to long-term and effective treatment strategies.
A study published in Molecular Genetics and Metabolism found that riluzole slows the progression of Niemann-Pick disease type C1 by reducing glutamate toxicity, increasing mouse survival by 12%. Researchers believe similar drugs may help slow disease progression in patients with NPC1.
Researchers at Universidad Complutense de Madrid have discovered alterations caused by ALS in the retina, which can be used as biomarkers for diagnosis and treatment monitoring. The study found changes in microglial cells and ganglion cell loss, with modifications evolving over the course of the disease.
A study published in Brain Pathology found elevated levels of tau protein in the brains of people with ALS who carry a mutation in the C9orf72 gene. The researchers also identified new genetic mutations in the tau gene and discovered that the ratio of different forms of tau protein may be an indicator of disease progression.
Researchers at Massachusetts General Hospital discovered that reducing abnormal tau can reverse mitochondrial dysfunction and oxidative stress in ALS. By targeting tau with a specific degrader, the study suggests a promising new treatment strategy for this degenerative disease.
A collaboration led by Scripps Research Institute successfully treated C9 ALS/FTD in mice using a novel RNA-hunting compound that recruits the cell's own virus fighter. The compound eliminated 70% of toxic protein fragments and removed most hallmarks of the disease from patient-derived nerve cells.
A new study suggests that vigorous exercise during leisure time is not associated with an increased risk of developing amyotrophic lateral sclerosis (ALS). However, intense physical activity at work hours was linked to a higher risk, possibly due to repetitive motion or exposure to chemicals. Moderate exercise, even after symptoms begi...
A study published in Cell Metabolism identified a protein called neurturin as crucial for muscle health, improving metabolic rates, motor function and exercise capacity. Mice genetically modified to produce more neurturin had increased resistance to degeneration in neurons associated with ALS.
Researchers at University of Illinois Chicago found a potential direct connection between neurodegenerative diseases, such as Alzheimer's disease, amyotrophic lateral sclerosis (ALS), glaucoma, and herpesvirus. The study suggests OPTN protein restricts HSV-1 virus spread in cells.
A large epidemiology study found associations between higher HDL and apoA1 levels with a lower risk of ALS. Lower LDL and apoB levels were also linked to decreased risk. These findings may support population screening and preventative therapy for ALS.
A new study from Salk Institute researchers found that a critical threshold of miR-218 levels determines the development of ALS in animal models. The study sheds light on the complex control of gene expression and its implications for treating neurological disorders.
Researchers have identified a novel genetic marker, rs139185008, that distinguishes C9orf72 repeat expansion carriers from non-carriers in large population-based cohorts. This SNP is strongly associated with patients having a clinical diagnosis of FTLD and motor neuron disease ALS.
Researchers at The Francis Crick Institute successfully reversed a key hallmark of motor neurone disease by blocking the activity of an enzyme called VCP. This breakthrough, published in Brain Communications, suggests that the abnormal accumulation of proteins involved in RNA regulation might be a factor contributing to the disease.
A recent study discovered that brain cells cannot maintain the myelin sheath in the absence of the TDP-43 protein. Restoring cholesterol levels has been proposed as a potential therapeutic strategy for neurodegenerative diseases associated with TDP-43. The research found that oligodendrocytes, responsible for producing myelin, have def...
A study published in Science Translational Medicine identified a common cellular defect in ALS that can be treated with an antisense oligonucleotide drug. Researchers found that the accumulation of CHMP7 protein in the nucleus leads to nuclear pore injury and TDP-43 mislocalization, ultimately causing cell death.
A distinctive inflammatory signature has been found in C90RF72 ALS patients, characterized by an increase in pro-inflammatory molecules in serum and cerebrospinal fluid. This finding informs the development of targeted anti-inflammatory therapies for this subgroup of ALS patients.
Researchers identified a new gene, TP73, associated with an increased risk of sporadic ALS. Mutations in this gene have been found to interfere with nerve cell health and lead to abnormal cell differentiation and increased cell death. This discovery provides a potential target for therapy development.
A new study found that networks of nerve cells in the spinal cord called inhibitory interneurons lose connection to motor neurons, which could explain why motor neurons die in ALS. This loss happens before motor neuron death and affects fast-twitch motor neurons first.
Researchers link ALS to a unique genetic mutation affecting lipid metabolism, providing clues for a novel therapy and understanding the disease's progression. The study reveals slower symptom onset and longer survival rates in children compared to adults with ALS.
A revolutionary assistive technology called Earswitch allows people with Motor Neurone Disease (MND) to communicate by tensing a tiny muscle in their ear. The device uses the tensor tympani muscle, which can be controlled voluntarily, and offers a new way for individuals with severe communications restrictions to express themselves.
A new study reveals that protein Rab2 is essential for effective nerve cell signaling in the central nervous system. The researchers found that when Rab2 is absent or dysfunctional, signal molecules accumulate in axons like a traffic jam.
Researchers found that Staufen1 accumulates in brains of patients with neurodegenerative disorders, disrupting normal cellular function. Lowering Staufen1 levels may improve pathology and rid cells of stress granules, a key finding for potential treatment approaches.
Researchers have identified a neuroprotective pathway that sustains the nucleocytoplasmic RAN gradient, suppressing Lou Gehrig's Disease. The LSM12-EPAC1 pathway normalizes abnormal RAN concentration differences, restoring cellular function.
Researchers at Case Western Reserve University have determined the structure of protein fibrils linked to Lou Gehrig's disease and other neurodegenerative disorders. The findings provide clues on how toxic proteins clump and spread between nerve cells in the brain, potentially leading to the development of new treatments.
Researchers at the Francis Crick Institute have identified the key cellular change that leads to harmful astrocytes in amyotrophic lateral sclerosis (ALS). The discovery could lead to new therapies to slow disease progression and is also relevant to other neurodegenerative diseases like Parkinson's and Alzheimer's. Understanding this c...
Researchers have identified a new signaling pathway that regulates the production of RNA-protein complexes in neurons, which are overproduced in neurodegenerative diseases such as ALS and senile dementia. This discovery may lead to better understanding and potential therapeutic options for these conditions.
Scientists at Northwestern University have identified a compound that eliminates degeneration of upper motor neurons in ALS, a neurodegenerative disease. After 60 days of treatment, diseased brain cells regain health and function like healthy control neurons.
Researchers found higher than expected genetic changes in a group of 100 MND patients, suggesting routine genetic testing may be beneficial. The study recommends genetic testing for all MND patients, regardless of family history, to improve disease subclassification and tailored treatments.
Researchers identify DNA-RNA hybrids as a key factor in ALS progression, leading to increased genomic damage and genetic instability. This breakthrough opens new avenues for understanding the disease's molecular basis and developing therapies to slow its evolution.
A novel method detects conformational changes in TDP-43 protein in ALS patients' CSF, showing high sensitivity and specificity. The technology has potential for diagnosing and developing clinical therapies for this fatal neurodegenerative disease.
Researchers at the University of Sheffield discovered a genetic risk factor for MND in non-coding DNA that can be targeted by SynCav1, potentially halting or preventing disease progression. The study built on patient data from Project MinE and could lead to personalized medicine for MND patients.
The Canadian Medical Association Journal published a new ALS guideline establishing a patient-focused approach to manage the disease. The guideline provides recommendations on communication, disease-modifying therapies, multidisciplinary care, and caregiver support.
Researchers have developed novel Selenium-based compounds that can stabilize the SOD1 protein, which causes ALS. These compounds show improved in vitro therapeutic effects and demonstrate disease onset delay in an ALS mouse model. The findings hold promise for a new class of drug candidates for ALS treatment.
Researchers at the University of Maryland School of Medicine have identified a new genetic defect linked to amyotrophic lateral sclerosis (ALS), a devastating condition causing progressive paralysis and mental deterioration. The discovery may lead to new treatments for ALS, with potential implications for other neurodegenerative diseases.
A study from North Carolina State University has identified blood plasma metabolite markers that can aid in ALS diagnosis, rule out environmental neurotoxin involvement, and predict disease progression. Elevated creatine levels and decreased creatinine and methylhistidine were found in ALS patients.
Scientists discovered biological markers in teeth of children who later developed ALS, shedding light on the disease's early stages and potential preventive strategies. The study found abnormal metal uptake patterns, suggesting a link between environmental factors and disease onset.
A study published in Frontiers in Molecular Neuroscience reveals the molecular underpinnings of electrical signals from potassium and sodium ion channels within neurons. The research identifies potential targets for future treatment strategies using existing drugs approved by the FDA.
Researchers investigated the association between stress-related disorders and neurodegenerative diseases in Sweden's national health registers. Stress-related disorders were found to be associated with an increased risk of these diseases.
A recent animal study found that adding L-serine to the diet of vervets exposed to cyanotoxin BMAA significantly reduced signs of ALS-like pathology. The study provides a promising model for understanding ALS development and potential treatments.
A study by Michigan Medicine team discovered that repeat expansions cause neurodegenerative diseases but also found normal functions of these repeats in regulating protein production in healthy nerve cells. The research suggests a potential pathway for treating Fragile X syndrome and other disorders.
A new study identified Gemin3 as a molecular 'bridge' between genes causing amyotrophic lateral sclerosis (ALS), a neurodegenerative disease. The research holds promise for developing treatments effective for a broad range of ALS patients.
Researchers at KBRI found a new molecular mechanism that can inhibit neuronal degeneration by TDP-43, which is a major cause of dementia and Lou Gehrig's disease. The discovery reveals a potential therapeutic strategy to remove abnormal protein accumulation in neurons of patients with dementia.
A recent study by Cold Spring Harbor Laboratory has made significant strides in understanding the role of proteins called TDP-43 in ALS. The researchers found that TDP-43 aggregates in nerve cells can cause a toxic effect, leading to paralysis. This discovery opens up new avenues for developing effective treatments and therapies.
Researchers found that ALS patients with a specific genetic variation in the IL6 receptor gene experience more severe symptoms and faster disease progression. The study suggests this polymorphism may serve as a target for new treatments and lay the groundwork for future clinical trials.
Amyotrophic Lateral Sclerosis (ALS) researchers found that aggregation of TDP-43 is not harmful but actually protects cells. This discovery challenges the assumption that alleviating protein aggregates is necessary to treat neurodegenerative diseases like ALS. The study opens doors to radically new therapeutic approaches if aggregation...
Researchers at Neuroscience 2019 announce new gene therapy research promising to prevent, treat, and reverse incurable neurological disorders. Successes in restoring lost functions in animal models of neurological diseases are discussed, as well as technique advancements that may improve future treatments.
Researchers at Oregon State University have made an important advance in understanding why certain cells in the nervous system are prone to breaking down and dying, which is what happens in patients with ALS. The study suggests that a protein chaperone called heat shock protein 90 may be critical to neuron survival.
Scientists at MSD and Francis Crick Institute are working together to better understand Motor Neurone Disease, a devastating disease with no current treatments. The collaboration aims to identify key mechanisms that can kill motor neurons and build scientific understanding for future treatments.
Northwestern University scientists have received a $3.1 million grant to investigate drug therapies for ALS, targeting protein aggregation and upper motor neurons. Promising early results suggest compounds may have broader applications for neurodegeneration.
Researchers found that protein clumps in ALS neurons can be triggered by cellular stress and may provide a potential target for new therapies. Chemical compounds have been identified to prevent this stress-induced accumulation, offering a promising starting point for treating the disease.
Increasing Klotho levels improves neurological deficits and prolongs life span in an experimental ALS model. Brain immune cells also play a crucial role in protecting the brain against inflammation and motor neuron loss.
A $2.88 million NIH grant supports Jingsong Zhou's work to preserve mitochondria and understand the mechanisms behind ALS deterioration. Her novel approach investigates the theory that ALS affects the physiology of the whole body through defective cells in multiple organs.
Researchers found a critical structure within TDP-43 that causes nerve cell death in ALS and FTD. Modifying this structure could lead to new therapies for these devastating diseases.
Researchers found that the most common genetic cause of ALS, C9orf72 mutation, leads to toxic dipeptide repeat polypeptides (DPRs) disrupting nucleolar assembly. Longer DPRs are more toxic to cells, highlighting a potential prognostic value for ALS patients.
St. Jude scientists discover that ULK1 and ULK2 break down stress granules, which build up toxic proteins that kill muscle and brain cells in diseases including IBM, ALS, and FTD. Boosting these enzymes could help treat the conditions.